Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma
- Autores
- García, Alejandro; Recondo, Gonzalo; Greco, Martín; de la Vega, Máximo; Perazzo, Florencia; Avagnina, Alejandra; Denninghoff, Valeria Cecilia
- Año de publicación
- 2020
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Lung cancer is the leading cause of cancer-related death worldwide. Recent advances in the management of non-small cell carcinoma are focused on the discovery of targeted therapies and novel immunotherapy strategies for patients with advanced disease. Treatment with anti PD-(L)1 immune checkpoint inhibitors requires the development of predictive biomarkers to select those patients that can most benefit from these therapies. Several immunohistochemical biomarkers have been developed in different technological platforms. However, the most useful and accessible for the daily clinical practice need to be selected. The objective of this study was to compare PD-L1 expression by automated immunohistochemistry in lung adenocarcinoma (ADC) FFPE samples with clones 28-8 and SP263 performed with the BenchMark GX automated staining instrument. To further determine interobserver agreement between two pathologists, and to correlate the results with histologic and pathology variables. FFPE tissue from 40 samples obtained from patients with lung ADC were reviewed retrospectively. Among all studied specimens, 53% of samples presented <1% of positive tumor cells with the 28-8 clone and 50% had <1% of PD-L1 expression in tumor cells with the SP263 clone; PD-L1 expression between ≥1 and <5% was observed in 18% and 24%; ≥5 and <50% PD-L1 expression in 18% and 21%; and ≥50% PD-L1 expression in 11% and 5% of samples, respectively. Similar results between antibodies were observed in 84% of cases for each of the four PD-L1 cutoff groups (Pearson's score 0.90, p < 0.00001). The interobserver degree of agreement calculated with Kappa was 0.75 (95%CI: 0.57–0.93), z = 7.08; p < 0.001. Lepidic, acinar and mucinous patterns had predominantly <1% PD-L1 expression, and the solid pattern subtype had high levels of PD-L1 staining using both clones. PD-L1 expression in less than 1% of tumor cells was similar in stages I/II compared to III/IV. No significant differences were observed in PD-L1 staining and quantification pattern between IHC antibodies 28-8 and SP263.
Fil: García, Alejandro. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
Fil: Recondo, Gonzalo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina
Fil: Greco, Martín. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
Fil: de la Vega, Máximo. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
Fil: Perazzo, Florencia. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
Fil: Avagnina, Alejandra. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina
Fil: Denninghoff, Valeria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina - Materia
-
28-8
BIOMARKERS
DIAGNOSTICS
HISTOPATHOLOGY
IMMUNOLOGY
LUNG ADENOCARCINOMA
ONCOLOGY
PATHOLOGY
PD-L1
SP263 - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/145938
Ver los metadatos del registro completo
id |
CONICETDig_d5aab7053f90b275c17e1e72cbe8358c |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/145938 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinomaGarcía, AlejandroRecondo, GonzaloGreco, Martínde la Vega, MáximoPerazzo, FlorenciaAvagnina, AlejandraDenninghoff, Valeria Cecilia28-8BIOMARKERSDIAGNOSTICSHISTOPATHOLOGYIMMUNOLOGYLUNG ADENOCARCINOMAONCOLOGYPATHOLOGYPD-L1SP263https://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Lung cancer is the leading cause of cancer-related death worldwide. Recent advances in the management of non-small cell carcinoma are focused on the discovery of targeted therapies and novel immunotherapy strategies for patients with advanced disease. Treatment with anti PD-(L)1 immune checkpoint inhibitors requires the development of predictive biomarkers to select those patients that can most benefit from these therapies. Several immunohistochemical biomarkers have been developed in different technological platforms. However, the most useful and accessible for the daily clinical practice need to be selected. The objective of this study was to compare PD-L1 expression by automated immunohistochemistry in lung adenocarcinoma (ADC) FFPE samples with clones 28-8 and SP263 performed with the BenchMark GX automated staining instrument. To further determine interobserver agreement between two pathologists, and to correlate the results with histologic and pathology variables. FFPE tissue from 40 samples obtained from patients with lung ADC were reviewed retrospectively. Among all studied specimens, 53% of samples presented <1% of positive tumor cells with the 28-8 clone and 50% had <1% of PD-L1 expression in tumor cells with the SP263 clone; PD-L1 expression between ≥1 and <5% was observed in 18% and 24%; ≥5 and <50% PD-L1 expression in 18% and 21%; and ≥50% PD-L1 expression in 11% and 5% of samples, respectively. Similar results between antibodies were observed in 84% of cases for each of the four PD-L1 cutoff groups (Pearson's score 0.90, p < 0.00001). The interobserver degree of agreement calculated with Kappa was 0.75 (95%CI: 0.57–0.93), z = 7.08; p < 0.001. Lepidic, acinar and mucinous patterns had predominantly <1% PD-L1 expression, and the solid pattern subtype had high levels of PD-L1 staining using both clones. PD-L1 expression in less than 1% of tumor cells was similar in stages I/II compared to III/IV. No significant differences were observed in PD-L1 staining and quantification pattern between IHC antibodies 28-8 and SP263.Fil: García, Alejandro. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; ArgentinaFil: Recondo, Gonzalo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; ArgentinaFil: Greco, Martín. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; ArgentinaFil: de la Vega, Máximo. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; ArgentinaFil: Perazzo, Florencia. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; ArgentinaFil: Avagnina, Alejandra. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; ArgentinaFil: Denninghoff, Valeria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; ArgentinaElsevier2020-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/145938García, Alejandro; Recondo, Gonzalo; Greco, Martín; de la Vega, Máximo; Perazzo, Florencia; et al.; Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma; Elsevier; Heliyon; 6; 6; 6-2020; 1-42405-8440CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S2405844020309610info:eu-repo/semantics/altIdentifier/doi/10.1016/j.heliyon.2020.e04117info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:10:33Zoai:ri.conicet.gov.ar:11336/145938instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:10:33.393CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma |
title |
Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma |
spellingShingle |
Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma García, Alejandro 28-8 BIOMARKERS DIAGNOSTICS HISTOPATHOLOGY IMMUNOLOGY LUNG ADENOCARCINOMA ONCOLOGY PATHOLOGY PD-L1 SP263 |
title_short |
Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma |
title_full |
Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma |
title_fullStr |
Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma |
title_full_unstemmed |
Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma |
title_sort |
Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma |
dc.creator.none.fl_str_mv |
García, Alejandro Recondo, Gonzalo Greco, Martín de la Vega, Máximo Perazzo, Florencia Avagnina, Alejandra Denninghoff, Valeria Cecilia |
author |
García, Alejandro |
author_facet |
García, Alejandro Recondo, Gonzalo Greco, Martín de la Vega, Máximo Perazzo, Florencia Avagnina, Alejandra Denninghoff, Valeria Cecilia |
author_role |
author |
author2 |
Recondo, Gonzalo Greco, Martín de la Vega, Máximo Perazzo, Florencia Avagnina, Alejandra Denninghoff, Valeria Cecilia |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
28-8 BIOMARKERS DIAGNOSTICS HISTOPATHOLOGY IMMUNOLOGY LUNG ADENOCARCINOMA ONCOLOGY PATHOLOGY PD-L1 SP263 |
topic |
28-8 BIOMARKERS DIAGNOSTICS HISTOPATHOLOGY IMMUNOLOGY LUNG ADENOCARCINOMA ONCOLOGY PATHOLOGY PD-L1 SP263 |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.2 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Lung cancer is the leading cause of cancer-related death worldwide. Recent advances in the management of non-small cell carcinoma are focused on the discovery of targeted therapies and novel immunotherapy strategies for patients with advanced disease. Treatment with anti PD-(L)1 immune checkpoint inhibitors requires the development of predictive biomarkers to select those patients that can most benefit from these therapies. Several immunohistochemical biomarkers have been developed in different technological platforms. However, the most useful and accessible for the daily clinical practice need to be selected. The objective of this study was to compare PD-L1 expression by automated immunohistochemistry in lung adenocarcinoma (ADC) FFPE samples with clones 28-8 and SP263 performed with the BenchMark GX automated staining instrument. To further determine interobserver agreement between two pathologists, and to correlate the results with histologic and pathology variables. FFPE tissue from 40 samples obtained from patients with lung ADC were reviewed retrospectively. Among all studied specimens, 53% of samples presented <1% of positive tumor cells with the 28-8 clone and 50% had <1% of PD-L1 expression in tumor cells with the SP263 clone; PD-L1 expression between ≥1 and <5% was observed in 18% and 24%; ≥5 and <50% PD-L1 expression in 18% and 21%; and ≥50% PD-L1 expression in 11% and 5% of samples, respectively. Similar results between antibodies were observed in 84% of cases for each of the four PD-L1 cutoff groups (Pearson's score 0.90, p < 0.00001). The interobserver degree of agreement calculated with Kappa was 0.75 (95%CI: 0.57–0.93), z = 7.08; p < 0.001. Lepidic, acinar and mucinous patterns had predominantly <1% PD-L1 expression, and the solid pattern subtype had high levels of PD-L1 staining using both clones. PD-L1 expression in less than 1% of tumor cells was similar in stages I/II compared to III/IV. No significant differences were observed in PD-L1 staining and quantification pattern between IHC antibodies 28-8 and SP263. Fil: García, Alejandro. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina Fil: Recondo, Gonzalo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina Fil: Greco, Martín. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina Fil: de la Vega, Máximo. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina Fil: Perazzo, Florencia. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina Fil: Avagnina, Alejandra. Centro de Educación Médica e Investigaciones Clínicas "Norberto Quirno"; Argentina Fil: Denninghoff, Valeria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. CEMIC-CONICET. Centro de Educaciones Médicas e Investigaciones Clínicas "Norberto Quirno". CEMIC-CONICET; Argentina |
description |
Lung cancer is the leading cause of cancer-related death worldwide. Recent advances in the management of non-small cell carcinoma are focused on the discovery of targeted therapies and novel immunotherapy strategies for patients with advanced disease. Treatment with anti PD-(L)1 immune checkpoint inhibitors requires the development of predictive biomarkers to select those patients that can most benefit from these therapies. Several immunohistochemical biomarkers have been developed in different technological platforms. However, the most useful and accessible for the daily clinical practice need to be selected. The objective of this study was to compare PD-L1 expression by automated immunohistochemistry in lung adenocarcinoma (ADC) FFPE samples with clones 28-8 and SP263 performed with the BenchMark GX automated staining instrument. To further determine interobserver agreement between two pathologists, and to correlate the results with histologic and pathology variables. FFPE tissue from 40 samples obtained from patients with lung ADC were reviewed retrospectively. Among all studied specimens, 53% of samples presented <1% of positive tumor cells with the 28-8 clone and 50% had <1% of PD-L1 expression in tumor cells with the SP263 clone; PD-L1 expression between ≥1 and <5% was observed in 18% and 24%; ≥5 and <50% PD-L1 expression in 18% and 21%; and ≥50% PD-L1 expression in 11% and 5% of samples, respectively. Similar results between antibodies were observed in 84% of cases for each of the four PD-L1 cutoff groups (Pearson's score 0.90, p < 0.00001). The interobserver degree of agreement calculated with Kappa was 0.75 (95%CI: 0.57–0.93), z = 7.08; p < 0.001. Lepidic, acinar and mucinous patterns had predominantly <1% PD-L1 expression, and the solid pattern subtype had high levels of PD-L1 staining using both clones. PD-L1 expression in less than 1% of tumor cells was similar in stages I/II compared to III/IV. No significant differences were observed in PD-L1 staining and quantification pattern between IHC antibodies 28-8 and SP263. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-06 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/145938 García, Alejandro; Recondo, Gonzalo; Greco, Martín; de la Vega, Máximo; Perazzo, Florencia; et al.; Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma; Elsevier; Heliyon; 6; 6; 6-2020; 1-4 2405-8440 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/145938 |
identifier_str_mv |
García, Alejandro; Recondo, Gonzalo; Greco, Martín; de la Vega, Máximo; Perazzo, Florencia; et al.; Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma; Elsevier; Heliyon; 6; 6; 6-2020; 1-4 2405-8440 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://linkinghub.elsevier.com/retrieve/pii/S2405844020309610 info:eu-repo/semantics/altIdentifier/doi/10.1016/j.heliyon.2020.e04117 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842980532008255488 |
score |
12.993085 |